Amsterdam - Delayed Quote EUR

Galapagos NV (GLPG.AS)

Compare
21.52
-0.56
(-2.54%)
As of 4:33:21 PM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
275,649
275,649
239,724
241,249
234,384
Cost of Revenue
34,863
34,863
--
--
1,629
Gross Profit
240,786
240,786
239,724
241,249
483,217
Operating Expense
429,124
429,124
327,987
372,306
405,949
Operating Income
-188,338
-188,338
-88,263
-131,057
-171,565
Net Non Operating Interest Income Expense
89,458
89,458
77,636
8,709
-9,296
Other Income Expense
95,795
95,795
16,252
51,499
61,462
Pretax Income
-3,085
-3,085
5,625
-70,849
-119,402
Tax Provision
-1,803
-1,803
9,613
572
1,389
Net Income Common Stockholders
74,082
74,082
211,697
-217,991
-103,231
Diluted NI Available to Com Stockholders
74,082
74,082
211,697
-217,991
-103,231
Basic EPS
1.12
--
3.21
-3.32
-1.58
Diluted EPS
1.12
--
3.21
-3.32
-1.58
Basic Average Shares
65,897
--
65,884
65,659.94
65,500
Diluted Average Shares
65,897
--
65,884
65,659.94
65,500
Total Operating Income as Reported
-188,338
-188,338
-88,263
-131,056
-171,568
Total Expenses
463,987
463,987
327,987
372,306
405,949
Net Income from Continuing & Discontinued Operation
74,082
74,082
211,697
-217,991
-103,231
Normalized Income
-76,960.05
-76,960.05
-16,827.08
-112,105.21
-165,658.26
Interest Income
89,773
89,773
79,608
18,094
2,865
Interest Expense
911
911
1,770
9,155
11,592
Net Interest Income
89,458
89,458
77,636
8,709
-9,296
EBIT
-2,174
-2,174
7,395
-61,694
-107,810
EBITDA
43,325
43,325
51,037
3,872
-73,174
Reconciled Cost of Revenue
2,536
2,536
--
--
1,629
Reconciled Depreciation
45,499
45,499
43,642
65,566
34,636
Net Income from Continuing Operation Net Minority Interest
-1,282
-1,282
-3,988
-71,421
-120,791
Total Unusual Items Excluding Goodwill
95,795
95,795
16,252
51,499
61,462
Total Unusual Items
95,795
95,795
16,252
51,499
61,462
Normalized EBITDA
-52,470
-52,470
34,785
-47,627
-134,636
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
20,116.95
20,116.95
3,412.92
10,814.79
16,594.74
12/31/2021 - 5/6/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HLVX HilleVax, Inc.
1.4411
-0.61%
 
ASMB Assembly Biosciences, Inc.
8.61
-7.52%
 
SPRO Spero Therapeutics, Inc.
0.5702
-8.62%
 
NXTC NextCure, Inc.
0.3830
-3.53%
 
EPIX ESSA Pharma Inc.
1.5400
-2.53%
 
THRD Third Harmonic Bio, Inc.
3.4900
-2.25%
 
TBPH Theravance Biopharma, Inc.
8.38
-4.45%
 
SEER Seer, Inc.
1.6250
-2.11%
 
PHARM.AS Pharming Group N.V.
0.7055
-1.54%
 
BOLT Bolt Biotherapeutics, Inc.
0.3999
+1.14%